Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK targeting in N-RAS mutated metastatic melanoma.

Molecular cancer - 4 Mar 2014

Thumar Jaykumar, Shahbazian David, Aziz Saadia A, Jilaveanu Lucia B, Kluger Harriet M

Abstract excerpt

BACKGROUND: Gain of function mutations in B-RAF and N-RAS occur frequently in melanoma, leading to mitogen activating protein kinase (MAPK) pathway activation, and this pathway is the target of drugs in development. Our purpose was to study clinical characteristics of patients with mutations in t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Genes, ras
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to Melanoma

Share to Neoplasm Metastasis

Share to Proportional Hazards Models

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 24588908
DOI: 10.1186/1476-4598-13-45
PMCID: PMC3945937

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24588908-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK targeting in N-RAS mutated metastatic melanoma.PMID 24588908Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

The role of MEK inhibitors in the treatment of metastatic melanoma.Semantic proximity Read ↗

Targeted Therapy for Melanomas Without BRAF V600 Mutations.Semantic proximity Read ↗

MEK inhibitors for the treatment of NRAS mutant melanoma.Semantic proximity Read ↗

Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in MelanomaSemantic proximity Read ↗

[Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

V599EB-RAF is an Oncogene in MelanocytesSemantic proximity Read ↗

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.Semantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.Semantic proximity Read ↗

Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.